A detailed history of Edgestream Partners, L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Edgestream Partners, L.P. holds 44,194 shares of NBIX stock, worth $5.55 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
44,194
Previous 24,005 84.1%
Holding current value
$5.55 Million
Previous $3.31 Million 83.81%
% of portfolio
0.3%
Previous 0.17%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$130.86 - $143.19 $2.64 Million - $2.89 Million
20,189 Added 84.1%
44,194 $6.08 Million
Q1 2024

May 10, 2024

BUY
$130.4 - $143.74 $1.3 Million - $1.44 Million
10,002 Added 71.43%
24,005 $3.31 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $1.27 Million - $1.59 Million
11,957 Added 584.41%
14,003 $1.85 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $1 Million - $1.25 Million
-10,657 Reduced 83.89%
2,046 $230,000
Q2 2023

Aug 10, 2023

SELL
$89.53 - $104.87 $2.2 Million - $2.58 Million
-24,569 Reduced 65.92%
12,703 $1.2 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $1.8 Million - $2.35 Million
19,118 Added 105.31%
37,272 $3.77 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $999,432 - $1.19 Million
9,365 Added 106.55%
18,154 $2.17 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $333,148 - $390,272
3,620 Added 70.03%
8,789 $933,000
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $1.59 Million - $2.1 Million
-20,954 Reduced 80.21%
5,169 $504,000
Q1 2022

May 13, 2022

SELL
$72.45 - $94.81 $1.44 Million - $1.89 Million
-19,933 Reduced 43.28%
26,123 $2.45 Million
Q4 2021

Feb 15, 2022

BUY
$79.65 - $106.22 $3.67 Million - $4.89 Million
46,056 New
46,056 $3.92 Million
Q2 2021

Aug 10, 2021

SELL
$89.43 - $102.27 $792,081 - $905,805
-8,857 Closed
0 $0
Q1 2021

May 06, 2021

BUY
$87.57 - $119.4 $775,607 - $1.06 Million
8,857 New
8,857 $861,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Edgestream Partners, L.P. Portfolio

Follow Edgestream Partners, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Edgestream Partners, L.P. with notifications on news.